Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Obesity 3Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Melanoma 2Skin Neoplasms 1Metabolic Syndrome 1Kidney Neoplasms 1Inflammation 1Glioma 1Glioblastoma 1Dyslipidemias 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 16Radiotherapy 9Anastrozole 8Letrozole 7Chemotherapy, Adjuvant 7Specimen Handling 6Radiation 5Neoadjuvant Therapy 5Mastectomy, Segmental 5Biopsy 5Sentinel Lymph Node Biopsy 4Psychiatric Rehabilitation 4Mass Spectrometry 4Immunohistochemistry 4Gene Expression Profiling 4Early Intervention, Educational 4Counseling 4exemestane 3afimoxifene 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Methods 3Mastectomy 3Magnetic Resonance Spectroscopy 3Fatty Acids, Omega-3 3Chromatography, High Pressure Liquid 3pasireotide 2Trastuzumab 2Standard of Care 2Soybean Proteins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Intraductal, Noninfiltrating × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡